Various Tumours
Conditions
Interventions
single arm:autologous DC-CTL cell
Sponsors
University of Chinese academy of sciences Shenzhen hospital(guang ming)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 to 70 years, No gender limitation; 2.Patients diagnosed with cancer by histopathology or cytology; 3.(ECOG) Performance Status 0-2; 4.The survival of patients should longer than 3 months, and accept follow-up visit. 5.Patients with solid tumor still have residual lesions after treatment and are not suitable for or unwilling to accept other anti-tumor therapies such as radiotherapy and chemotherapy 6.Blood tumors are in remission after treatment and are not suitable for or are unwilling to receive radiotherapy or chemotherapy or other anti-tumor therapies; 7.Patients did not receive any anticancer therapy such as chemotherapy, radiotherapy and immunotherapy (such as immunosuppressive drugs) within 2-4 weeks before enrollment, and their previous treatment-related toxicity had recovered to <1 level at enrollment (except for low toxicity such as alopecia and peripheral neuritis). 8.The patient's venous passage is unobtrusive, which can meet the needs of intravenous infusion. 9.All the patients volunteer should rule out pregnancy until the follow-up completed. 10. The patients volunteer to join in the trial and sign the informed consents.
Exclusion criteria
Exclusion criteria: 1.Patients received high dose of corticosteroids (except for patients who received inhaled corticosteroids) within 1 week before enrollment; 2.Patient suffering from serious autoimmune diseases, immunodeficiency diseases or severe allergies; 3.Patients had uncontrolled infections within 4 weeks prior to enrollment; 4.Hepatitis C virus (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive; 5.Patients had participated in other clinical studies within 6 weeks prior to enrollment; 6.Patients suffering from mental illness; 7.Patients with substance abuse/addiction and medical, psychological or social conditions that may interfere with the study or have an impact on the evaluation of the study results; 8.The patient was alcohol dependent; 9.Women who are pregnant (positive for urine/blood pregnancy studies) or lactating; Men or women who have planned to give birth within the past 1 year; Patients were not guaranteed effective contraception during the study period; 10.Patients with a definite diagnosis of T-cell leukemia or T-cell lymphoma; 11.According to the researchers' judgment, the patients had other unsuitable conditions for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate, ORR;disease control rate, DCR;progression-free survival, PFS;overall survival, OS; | — |
Countries
China
Contacts
Public ContactShu Xu
University of Chinese Academy of Sciences Shenzhen Hospital (Guangming)
Outcome results
None listed